Abstract
As part of the 2017 Melanoma Bridge congress (November 30-December 2, 2017, Napoli, Italy), the great debate session featured counterpoint views from leading experts on three contemporary controversial clinical issues in the care of the melanoma patient. These were: (1) whether complete lymph node dissection should be routinely offered to all melanoma patients with sentinel lymph node-positive disease; (2) whether first-line treatment of BRAF-mutated melanoma should consist of BRAF-targeted therapy or immunotherapy with checkpoint inhibitors; and (3) whether combined or sequential administration of treatments should be the preferred option in the management of patients with advanced melanoma. Discussion of these three important issues and audience responses are reported here.
Original language | English (US) |
---|---|
Article number | 101 |
Pages (from-to) | 101 |
Number of pages | 1 |
Journal | Journal of translational medicine |
Volume | 16 |
Issue number | 1 |
DOIs | |
State | Published - Apr 17 2018 |
Keywords
- Combination
- Immunotherapy
- Lymphadenectomy
- Melanoma
- Targeted therapy
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology